The FDA granted Expanded Access authorization for the Cancer BioShield™ platform of ImmunityBio on August 28, 2025. The company is now engaging with regulators to update clinical guidelines.

The entities involved

• ImmunityBio →

  biotech company

  • ImmunityBio leadership is scheduled to discuss priorities during a meeting in London.Wed 05:30
• FDA →
  • FDA and HHS jointly presented food safety reforms, reviewing ultraprocessed food definitions and calling for congressional action on the GRAS program.06:54
  • FDA issued a warning letter to NeoGen regarding a product quality defect on October 7, 2026.Thu 17:56

Related events

• The FDA requested additional clinical data from Unicycive Therapeutics.Jun 29
• FDA approved a medical device from Abbott and supported a PARADIGM study based on data from the Cleveland Clinic.Oct 28
• Moderna and Merck are developing cancer vaccines in partnership, while Moderna is also seeking approval for its seasonal influenza vaccine.Jul 7